Moderna, Inc. - Common Stock (MRNA)

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 17.4% in the afternoon session after the company settled a long-running patent di...

The news is likely to come as a relief to many investors, Citi told investors in a research note.

It's not too late to get in on the action.

Following warnings from Iran over the closure of the Strait of Hormuz, President Donald Trump announced that the U.S. would extend risk insurance for maritime trade through the strait.

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines.

Moderna stock has crashed 90% — but is the market mispricing what comes next? 7 key questions on MRNA's cancer vaccine, cash runway, and upside case.

As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of its fourth-quarter 2025 financial results, a move that signals investor confidence in the company’s radical transformation. Once teetering on the edge of a [...]

The stock, after a few tough years, soared in the double-digits in January.

What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating.

Moderna made a fortune with COVID vaccines, but revenue has since declined.

Laffont's new addition may represent an exciting recovery story.

Moderna’s fourth quarter results were received positively by the market, reflecting a combination of better-than-expected revenue and effective cost management. Management cited the successful U.S. launch of MNEXT Spike, improved operational efficiency, and disciplined expense controls as key contributors. CEO Stéphane Bancel highlighted that operating expenses fell by 31% year over year, while President Stephen Hoge noted, “MNEXT Spike quickly became our leading product in the U.S.” The leadership acknowledged ongoing challenges, particularly the uncertainty caused by the FDA’s refusal to file letter on the mRNA-1010 flu vaccine, which management described as a source of “real challenges for businesses, patients, and the broader innovation ecosystem.”

Bargain-hunters should give these stocks a close look.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.9% in the afternoon session after the U.S. Food and Drug Administration (FDA) reversed an earlier decision and agreed to review the company's application for its new seasonal flu vaccine. 

So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy?